Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Luqiao Wang
Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Frontiers in Oncology
Cancer Research
Oncology
Related publications
Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)
BMJ Open
Medicine
Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination With Ibrutinib for Relapsed and/or Refractory CLL
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Older, Vulnerable Patients With Relapsed/Refractory Large B-Cell Lymphoma
Haematologica
Hematology
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Chimeric Antigen Receptor T-Cells (Car-T) for Refractory and Relapsed Burkitt's Lymphoma: Early Response in Pediatric Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cd30-Chimeric Antigen Receptor (Car) T Cells for Therapy of Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
